Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» bipolar disorder
bipolar disorder
Autobahn raises $100M on investor interest in neuropsych drugs
BioPharma Dive
Thu, 07/25/24 - 11:09 am
Autobahn Therapeutics
major depressive disorder
bipolar disorder
funding
ABX-002
FDA approves Vanda's drug for treatment of bipolar disorder
Reuters
Tue, 04/2/24 - 09:57 pm
Vanda Pharmaceuticals
bipolar disorder
FDA
Fanapt
The Neuropsychiatric Pipeline: 10 Late-Stage Therapies to Watch
BioSpace
Mon, 08/14/23 - 11:23 am
depression
Biogen
SAGE Therapeutics
zuranolone
Intra-Cellular Therapies
lumateperone
Alto Neuroscience
ALTO-100
schizophrenia
Karuna Therapeutics
KarXT
Cerevel Therapeutics
emraclidine
Acadia Pharmaceuticals
pimavanserin
Axesome Therapeutics
AXS-05
Alzheimer's agitation
NRx
NRX-101
bipolar disorder
Biohaven
troriluzole
OCD
VistaGen
fasedienol
social anxiety
Alvogen snags NRx's bipolar depression drug in $330M deal ahead of late-phase data drop
Fierce Biotech
Wed, 06/7/23 - 09:37 pm
Alvogen
bipolar disorder
NRX-101
clinical trials
Otsuka, Lundbeck gain FDA nod for longer-acting version of schizophrenia drug Abilify
Fierce Pharma
Mon, 05/1/23 - 10:04 am
Otsuka
Lundbeck
FDA
Abilify
Asimtufii
bipolar disorder
Intra-Cellular reports positive Phase III trial of Caplyta in MDD and bipolar depression
Clinical Trials Arena
Wed, 03/29/23 - 09:40 am
Intra-Cellular Therapies
clinical trials
Caplyta
major depressive disorder
bipolar disorder
FDA accepts Otsuka, Lundbeck filing for long-acting schizophrenia drug, teeing up April decision date
Fierce Pharma
Tue, 09/13/22 - 10:50 am
Otsuka
Lundbeck
schizophrenia
FDA
bipolar disorder
Abilify Maintena
A Win for AI: FDA Approves BioXCel Therapy for Bipolar Disorder and Schizophrenia
BioSpace
Wed, 04/6/22 - 07:47 pm
BioXcel
artificial intelligence
bipolar disorder
schizophrenia
FDA
Igalmi
Intra-Cellular Bipolar Drug Shows "Significant" Benefit in Depressive Episodes
BioSpace
Tue, 09/28/21 - 11:10 am
Intra-Cellular Therapies
clinical trials
lumateperone
bipolar disorder
Alkermes prepares for uncertain launch as FDA finally clears schizophrenia drug
Biopharma Dive
Tue, 06/1/21 - 10:37 pm
Alkermes
FDA
schizophrenia
bipolar disorder
Lybalvi
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
Xconomy
Sat, 10/10/20 - 11:36 pm
Alkermes
FDA
advisory panels
ALKS 3831
schizophrenia
bipolar disorder
5 FDA approval decisions to watch in the 4th quarter
BioPharma Dive
Wed, 09/30/20 - 10:45 am
FDA
drug approvals
vaccines
Pfizer
Moderna Therapeutics
COVID-19
Regeneron
EB3
ebola virus
Alkermes
ALKS-3831
schizophrenia
bipolar disorder
Bristol-Myers Squibb
liso-cel
non-Hodgkin lymphoma
roxadustat
FibroGen
chronic kidney disease
Intra-Cellular roars back on success in bipolar depression
BioPharma Dive
Wed, 09/9/20 - 08:07 pm
Intra-Cellular Therapeutics
bipolar disorder
lumateperone
clinical trials
BioXcel’s phase 3 schizophrenia film has blockbuster potential, say analysts
Pharmaforum
Fri, 09/4/20 - 10:11 am
BioXcel
schizophrenia
bipolar disorder
sublingual treatments
dexmedetomidine
clinical trials
Virtual FDA AdComm for Alkermes' ALKS 3831 adds new focus on drug-drug interactions
Fierce Biotech
Fri, 08/21/20 - 11:36 pm
Alkermes
schizophrenia
bipolar disorder
FDA
ALKS 3831
Sunovion’s SEP-4199 fails to meet primary endpoint in SEP380-201 trial
Pharmaceutical Business Review
Tue, 07/7/20 - 10:45 am
Sunovion
clinical trials
SEP-4199
bipolar disorder
AstraZeneca Sells off Seroquel Rights in U.S. and Canada
BioSpace
Tue, 12/3/19 - 10:44 pm
AstraZeneca
Cheplapharm
Seroquel
Seroquel XR
bipolar disorder
schizophrenia
Before 2019 closes, the FDA has 3 key approval decisions to make
Biopharma Dive
Wed, 11/27/19 - 12:43 pm
Allergan
ubrogepant
migraines
Amarin
Vascepa
Intra-Cellular Therapeutics
lumateperone
schizophrenia
bipolar disorder
drug approvals
FDA
Intra-Cellular optimistic on lumateperone's future in bipolar despite mixed Phase III results
BioCentury
Mon, 07/8/19 - 08:16 pm
Intra-Cellular Therapies
lumateperone
clinical trials
bipolar disorder
Allergan puts Vraylar on blockbuster track with new bipolar depression nod
Fierce Pharma
Tue, 05/28/19 - 12:21 pm
Allergan
FDA
Vraylar
bipolar disorder
Pages
1
2
3
4
next ›
last »